SecBot SecBot
144 ·Filed Oct 30, 2026

TAK

TAKEDA PHARMACEUTICAL CO LTD
NEUTRAL
Impact 2/10
Horizondays Processed17d 5h ago SEC0001493152-26-049485
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The sale is small relative to market cap and the insider's role is a business unit president, not the CEO/CFO. The prior tax-motivated sale pattern suggests this may be routine. Monitor for the actual sale on Form 4 and any subsequent insider selling patterns.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$20.87
T+0 close · Oct 30, 2026 · via day close
Latest settled
+1.05%
T+5 · $21.09 · next T+20 in 14d
Vs SPY
+0.98%
α at T+5
Latest observation
+4.16%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $20.87entry
  2. T+1 · 14d ago −0.57%α −0.87% · $20.75
  3. T+5 · 8d ago +1.05%α +0.98% · $21.09
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Teresa Bitetti, President of Takeda's Global Oncology Business Unit, filed a Form 144 to sell 46,609 American Depositary Shares (ADSs) with an approximate market value of $940,104. The sale is scheduled for or after November 1, 2026. The filing notes that a prior sale in August 2026 was to satisfy tax obligations related to share vesting, suggesting this proposed sale may also be for tax or routine portfolio management purposes.

Key Facts

  • Insider: Teresa Bitetti, President, Global Oncology Business Unit
  • Proposed sale of 46,609 ADSs, approximate value $940,104
  • Proposed sale date: on or after November 1, 2026
  • Prior sale of 50,012 ADSs on August 10, 2026 was to satisfy tax obligations from share vesting
  • Shares were acquired via vested Restricted Stock Unit Awards on July 30, 2024
  • Market cap of Takeda: $63.7 billion; sale represents ~0.0015% of market cap

Financial Impact

Proposed sale of $940,104 in ADSs, representing a negligible fraction of the company's $63.7B market cap.

dilution

Risk Factors

  • Form 144 signals intent to sell; the sale may not be completed.
  • If this sale is followed by larger insider sales or by other executives, it could indicate broader insider sentiment.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001493152-26-049485
Document: 0001493152-26-049485-index.html0001493152-26-049485
Document: 0001493152-26-049485.txt0001493152-26-049485

Track record

18 reports on TAK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
  2. Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  3. Oct 30, 202617d ago 144 Neutral 2/10 Viewing Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
  4. Oct 29, 202618d ago 6-K Neutral 4/10 No price data
  5. Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
  6. Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
  7. Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
  8. Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
  9. Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026